These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26999054)

  • 1. Identifying predictive markers for personalized treatment selection.
    Shen Y; Cai T
    Biometrics; 2016 Dec; 72(4):1017-1025. PubMed ID: 26999054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kernel machine testing for risk prediction with stratified case cohort studies.
    Payne R; Neykov M; Jensen MK; Cai T
    Biometrics; 2016 Jun; 72(2):372-81. PubMed ID: 26692376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kernel machine approach to testing the significance of multiple genetic markers for risk prediction.
    Cai T; Tonini G; Lin X
    Biometrics; 2011 Sep; 67(3):975-86. PubMed ID: 21281275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian predictive modeling for genomic based personalized treatment selection.
    Ma J; Stingo FC; Hobbs BP
    Biometrics; 2016 Jun; 72(2):575-83. PubMed ID: 26575856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Part 1. Statistical Learning Methods for the Effects of Multiple Air Pollution Constituents.
    Coull BA; Bobb JF; Wellenius GA; Kioumourtzoglou MA; Mittleman MA; Koutrakis P; Godleski JJ
    Res Rep Health Eff Inst; 2015 Jun; (183 Pt 1-2):5-50. PubMed ID: 26333238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omnibus risk assessment via accelerated failure time kernel machine modeling.
    Sinnott JA; Cai T
    Biometrics; 2013 Dec; 69(4):861-73. PubMed ID: 24328713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying optimal biomarker combinations for treatment selection through randomized controlled trials.
    Huang Y
    Clin Trials; 2015 Aug; 12(4):348-56. PubMed ID: 25948620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating marker-guided treatment selection strategies.
    Matsouaka RA; Li J; Cai T
    Biometrics; 2014 Sep; 70(3):489-499. PubMed ID: 24779731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations.
    Huber C; Benda N; Friede T
    Pharm Stat; 2019 Oct; 18(5):600-626. PubMed ID: 31270933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical learning of origin-specific statically optimal individualized treatment rules.
    van der Laan MJ; Petersen ML
    Int J Biostat; 2007; 3(1):Article 6. PubMed ID: 19122792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying optimal biomarker combinations for treatment selection via a robust kernel method.
    Huang Y; Fong Y
    Biometrics; 2014 Dec; 70(4):891-901. PubMed ID: 25124089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient screening of predictive biomarkers for individual treatment selection.
    Sugasawa S; Noma H
    Biometrics; 2021 Mar; 77(1):249-257. PubMed ID: 32294246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicategory individualized treatment regime using outcome weighted learning.
    Huang X; Goldberg Y; Xu J
    Biometrics; 2019 Dec; 75(4):1216-1227. PubMed ID: 31095722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing and estimation in marker-set association study using semiparametric quantile regression kernel machine.
    Kong D; Maity A; Hsu FC; Tzeng JY
    Biometrics; 2016 Jun; 72(2):364-71. PubMed ID: 26575303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post hoc subgroups in clinical trials: Anathema or analytics?
    Weisberg HI; Pontes VP
    Clin Trials; 2015 Aug; 12(4):357-64. PubMed ID: 26062595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian personalized treatment selection strategies that integrate predictive with prognostic determinants.
    Ma J; Stingo FC; Hobbs BP
    Biom J; 2019 Jul; 61(4):902-917. PubMed ID: 30786040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Quantitative Concordance Measure for Comparing and Combining Treatment Selection Markers.
    Zhang Z; Ma S; Nie L; Soon G
    Int J Biostat; 2017 Mar; 13(1):. PubMed ID: 28343164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing interaction between treatment and high-dimensional covariates in randomized clinical trials.
    Callegaro A; Spiessens B; Dizier B; Montoya FU; van Houwelingen HC
    Biom J; 2017 Jul; 59(4):672-684. PubMed ID: 27763683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine.
    Belhechmi S; Le Teuff G; De Bin R; Rotolo F; Michiels S
    BMC Bioinformatics; 2023 Mar; 24(1):96. PubMed ID: 36927444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some alternatives to asymptotic tests for the analysis of pharmacogenetic data using nonlinear mixed effects models.
    Bertrand J; Comets E; Chenel M; Mentré F
    Biometrics; 2012 Mar; 68(1):146-55. PubMed ID: 22049987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.